Daewoong Pharmaceutical, 28,000 Shares Net Bought by Institutions in Last 5 Days... Stock Price at 238,000 KRW (-13.61%)

Daewoong Pharmaceutical is trading at 238,000 KRW as of 11:30 AM on the 22nd, down 13.61% from the previous day. The trading volume is 294,804 shares, which is 93.93% of the previous day's volume. Daewoong Pharmaceutical is known as a leading pharmaceutical company manufacturing and selling drugs such as Urusa and Albis.

On December 17, researcher Lee Hyerin from KTB Investment & Securities stated, "After the US market closed early morning, the ITC final ruling was announced. A 21-month import ban order was issued. The market had already reflected the worst-case scenario of the ITC lawsuit results, so this is considered a positive issue. The preliminary ruling of a 10-year import ban was the worst case, and thus the value of Nabota’s export business was reflected as zero when calculating Daewoong Pharmaceutical’s target price. If the final ruling does not overturn the result, the punitive damages portion from Evolus must be considered, and this risk was factored into the target price." He set Daewoong Pharmaceutical’s target price at 130,000 KRW.

Over the past five days, individual investors have net bought 6,934 shares of Daewoong Pharmaceutical, while foreigners and institutions have net sold 9,535 shares and net bought 20,008 shares, respectively.

※ Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article creation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.